{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:12:52Z","timestamp":1783599172617,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA120528"],"award-info":[{"award-number":["R01 CA120528"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jtho.2021.06.014","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:29:28Z","timestamp":1625570968000},"page":"1925-1935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"16","author":[{"given":"Beow Y.","family":"Yeap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"De Rienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu R.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela E.","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary N.","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhien T.","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel D.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Vermilya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne E.","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Ovsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2021.06.014_bib1","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00268-019-05132-6","article-title":"Largely unchanged annual incidence and overall survival of pleural mesothelioma in the USA","volume":"43","author":"Keshava","year":"2019","journal-title":"World J Surg"},{"key":"10.1016\/j.jtho.2021.06.014_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11912-011-0177-9","article-title":"Malignant pleural mesothelioma","volume":"13","author":"Raja","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jtho.2021.06.014_bib3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","article-title":"Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients","volume":"117","author":"Sugarbaker","year":"1999","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2021.06.014_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/SLA.0000000000000903","article-title":"Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients","volume":"260","author":"Sugarbaker","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.jtho.2021.06.014_bib5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.06.014_bib6","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-18-2860","article-title":"Health-related quality of life impact from adding bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS IFCT-GFPC-0701 phase III trial","volume":"25","author":"Eberst","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.06.014_bib7","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2021.06.014_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2021.06.014_bib9","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jtho.2018.08.001","article-title":"Surgery in malignant pleural mesothelioma","volume":"13","author":"Bueno","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.06.014_bib10","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.06.014_bib11","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.06.014_bib12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.06.014_bib13","first-page":"497","article-title":"Standardizing surgical treatment in malignant pleural mesothelioma","volume":"1","author":"Rice","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2021.06.014_bib14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jnci\/djp061","article-title":"Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma","volume":"101","author":"Gordon","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2021.06.014_bib15","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/jnci\/95.8.598","article-title":"Using gene expression ratios to predict outcome among patients with mesothelioma","volume":"95","author":"Gordon","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2021.06.014_bib16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jnci\/djx175","article-title":"Quantitative clinical staging for patients with malignant pleural mesothelioma","volume":"110","author":"Gill","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2021.06.014_bib17","first-page":"554","article-title":"The value of inflammatory parameters in the prognosis of malignant mesothelioma","volume":"42","author":"Abakay","year":"2014","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.jtho.2021.06.014_bib18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A\u00a0novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.06.014_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.06.014_bib20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2021.06.014_bib21","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","article-title":"Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy","volume":"6","author":"Kao","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.06.014_bib22","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.06.014_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cllc.2012.03.011","article-title":"Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board","volume":"14","author":"Kao","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2021.06.014_bib24","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/crj.12574","article-title":"Relation between neutrophil\/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma","volume":"12","author":"\u00d6zy\u00fcrek","year":"2018","journal-title":"Clin Respir J"},{"key":"10.1016\/j.jtho.2021.06.014_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2021.06.014_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-10-0806","article-title":"Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma","volume":"17","author":"De Rienzo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.06.014_bib27","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.jtho.2021.06.014_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1148\/radiol.2291010898","article-title":"Receiver operating characteristic curves and their use in radiology","volume":"229","author":"Obuchowski","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.jtho.2021.06.014_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/sim.4780030207","article-title":"Regression modelling strategies for improved prognostic prediction","volume":"3","author":"Harrell","year":"1984","journal-title":"Stat Med"},{"key":"10.1016\/j.jtho.2021.06.014_bib30","series-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2010"},{"key":"10.1016\/j.jtho.2021.06.014_bib31","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-04-2181","article-title":"Validation of genomics-based prognostic tests in malignant pleural mesothelioma","volume":"11","author":"Gordon","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.06.014_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jmoldx.2016.07.011","article-title":"Validation of a gene expression test for mesothelioma prognosis in formalin-fixed paraffin-embedded tissues","volume":"19","author":"De Rienzo","year":"2017","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jtho.2021.06.014_bib33","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2021.06.014_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2021.06.014_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2021.06.014_bib36","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421022553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421022553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:47:50Z","timestamp":1761562070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086421022553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1556086421022553"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2021.06.014","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2021.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}